von Moos R, Caspar CB, Steiner R, Angst R, Inauen R, Schmieding K, Thürlimann B.
Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes.
Onkologie. 33(8-9): 447-50
Heinzerling LM, Anliker MD, Müller J, Schlaeppi M, von Moos R.
Sarcoidosis induced by interferon-a in melanoma patients: incidence, clinical manifestations, and management strategies.
J Immunother. Oct;33(8): 834-9
von Moos R, Roth A, Ruhstaller T, Widmer L, Uhlmann C, Cathomas R, Köberle D, Simcock M, Lanz D, Popescu R on behalf of the Swiss Group for Clinical Cancer Research (SAKK)
Oxaliplatin, irinotecan and capecitabine (OCX) for first line treatment of advanced / metastatic colorectal cancer: a phase I trial (SAKK 41/03).
Onkologie. 33(6): 295-9
Ruhstaller T, Templeton A, Ribi K, Schuller JC, Borner M, Thierstein S, von Moos R, Pederiva S. Lohri A, Lombriser N, von Briel C, Koeberle D, Popescu R.
Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02).
Onkologie. 33(5): 222-8
Fehr M, von Moos R, Furrer M, Cathomas R.
Spontaneous pneumothorax during chemotherapy.
Onkologie. 33(10): 527-30
von Moos R, Schaffner R, Cathomas R, Grimm B.
Intratumoral therapy with interferon-alpha in a locoregional advanced malignant blue nevus: a brief communication.
J Immunother. Jan; 33(1): 92-5
Padberg B, Frick H, Rost B, Winkler Ch, von Moos R.
Maligne retrorektale Tailgut-Zysten.
Schweiz Med. Forum. 10(26-27): 471-3
Greuter S, von Moos R.
Die antiemetische Prophylaxe bei Chemotherapie. Übersicht und Erläuterung aktueller Guidelines.
Schweizer Zeitschrift für Onkologie. 3
K. Zaman, C. Rochlitz, B. Thürlimann, S. Aebi, R. von Moos, Ch. Mamot, N. Gabriel, L. Rossier-Pansier, R. Stupp, S. Crowe, C. Ruegg.
CePO. MMP-9 as predicitive factor for response and progression free survival in breast cancer patients treated with bevacizumab and pegylated liposomal doxorubicin. A multicenter, single-arm phase II trial (SAKK 26/06). On behalf of the Swiss Group for Clinical Cancer Research (SAKK).
Poster presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS). San Antonio, Texas; December 2010
D. Koeberle, T. Ruhstaller, L. Jost, O. Pagani, K. Zaman, R. von Moos, C. Oehlschlegel, S. Crowe, C. Pilop, B. Thuerlimann.
Can resistance to Trastuzumab be reversed by endocrine therapy? Combination of Trastuzumab and letrozole after resistance to sequential Trastuzumab and aromatase inhibitor monotherapies in patients with ER-positive, HER-2 positive, advanced breast cancer: a proof-of-concept trial (SAKK 23/03). On behalf of the Swiss Group for Clinical Cancer Research (SAKK).
Poster presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS). San Antonio, Texas; December 2010
Stopeck A, Lipton A., Campbell-Baird C, von Moos R, Fan M, Haddock B, Braun A.
Acute-Phase Reactions Following Treatment With Zoledronic Acid or Denosumab: Results From a Randomized, Controlled Phase 3 Study in Patients with Breast Cancer and Bone Metastases.
Poster presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS). San Antonio, Texas; December 2010
C.S. Cleeland, D.L. Patrick, L. Fallowfield, R. von Moos, J. Body, B. Egerdie, D. Damyanov, Y. Qian, A. Braun, K. Chung.
Effects of denosumab vs zoledronic acid (ZA) on pain in patients (PTS) with advanced cancer and bone metastases: An integrated analysis of 3 pivotal trials.
Annals of Oncology, 2010: ESMO Annual Meeting, Vol. 21, Suppl. 8, October 2010
R. Cathomas, C. Rothermund, R. von Moos, D.C. Betticher, R. Winterhalder, C. Droege, D. Siciliano, D.R. Berthold, M. Pless, S. Gillessen.
Cetuximab in combination with Docetaxel in patients (PTS) with metastatic castration resistant (MCRPC) and docetaxel-refractory prostate cancer: Final analysis of the multicenter phase II trial SAKK 08/07.
Annals of Oncology, 2010: ESMO Annual Meeting, Vol. 21, Suppl. 8, October 2010
R. Winterhalder, G. Delmore, P. Hösli, A. Hügli-Dayer, M. Mannhart, F. Otto, S. Pederiva, M. van Lier, S. Nick, R. von Moos.
Impact of different patient management approaches on the control of capecitabine-related adverse events: A prospective cohort analysis from SAEDA II.
Annals of Oncology, 2010: ESMO Annual Meeting, Vol. 21, Suppl. 8, October 2010
R. von Moos, G. Delmore, P. Hösli, A. Hügli-Dayer, M. Mannhart, F. Otto, S. Pederiva, M. van Lier, S. Nick, R. Winterhalder.
Initial treatment dose and reasons for dose adjustement during oral capecitabine chemotherapy.
Annals of Oncology, 2010: ESMO Annual Meeting, Vol. 21, Suppl. 8, October 2010
M. Pless, D.C. Betticher, M. Buess, R. von Moos, U. Weinberg, E. Kirson, Y. Palti.
A phase II study of tumor treating fields (TTFIELDS) in combination with Pemetrexed for advanced non small cell lung cancer (NSCLC).
Annals of Oncology, 2010: ESMO Annual Meeting, Vol. 21, Suppl. 8, October 2010
B. Thürlimann, C. Rochlitz, S. P. Aebi, U. Güth, R. von Moos, A. Müller, L. U. Von Rohr, M. Baumann, J. B. Huober.
Trastuzumab (T) treatment beyond progression in metastatic breast cancer (MBC): Patterns of care in Swiss clinical practice.
Journal of Clinical Oncology, 2010:ASCO Annual Meeting Proceedings, Part I. Vol. 28, No 15S (Supplement)
R. Cathomas, C. Rothermundt, R. von Moos, D. C. Betticher, R. C. Winterhalder, C. Droege, D. Siciliano, D. R. Berthold, M. Pless, S. Gillessen.
Cetuximab in combination with docetaxel in patients (pts) with metastatic castration resistant (mCRPC) and docetaxel-refractory prostate cancer: A multicenter phase II trial (SAKK 08/07).
Journal of Clinical Oncology, 2010:ASCO Annual Meeting Proceedings, Part I. Vol. 28, No 15S (Supplement)
R. Dummer, O. Michielin, B. Seifert, A. F. Ochsenbein, R. Cathomas, M. R. Schlaeppi, M. Simcock, S. Gillessen, S. M. Goldinger, R. von Moos.
First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07).
Journal of Clinical Oncology, 2010:ASCO Annual Meeting Proceedings, Part I. Vol. 28, No 15S (Supplement)
A. F. Ochsenbein, P. Schraml, D. Mihic, M. Simcock, R. Dummer, O. Michielin, B. Seifert, M. R. Schlaeppi, H. Moch, R. von Moos.
MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab (SAKK 50/07).
Journal of Clinical Oncology, 2010:ASCO Annual Meeting Proceedings, Part I. Vol. 28, No 15S (Supplement)
G. Fuerstenberger, E. Boneberg, M. Simcock, R. Dummer, S. M. Goldinger, O. Michielin, B. Seifert, A. F. Ochsenbein, M. R. Schlaeppi, R. von Moos.
Predictive and prognostic potential of angiogenic serum factors and circulating endothelial cells in metastatic melanoma patients receiving temozolamide plus bevacizumab (SAKK 50/07).
Journal of Clinical Oncology, 2010:ASCO Annual Meeting Proceedings, Part I. Vol. 28, No 15S (Supplement)
A. Lipton, A. Stopeck, R. von Moos, D. H. Henry, G. E. Richardson, G. I. Rodriguez, H. P. Bourgeois, C. Ke, S. Jun, R. D. Dansey.
A meta-analysis of results from two randomized, double-blind studies of denosumab versus zoledronic acid (ZA) for treatment of bone metastases.
Journal of Clinical Oncology, 2010:ASCO Annual Meeting Proceedings, Part I. Vol. 28, No 15S (Supplement)
S. Vadhan-Raj, D. H. Henry, R. von Moos, V. Hungria, F. Goldwasser, G. Scagliotti, J. Wang, S. Jun, R. D. Dansey, H. Yeh.
Denosumab in the treatment of bone metastases from advanced cancer or multiple myeloma (MM): Analyses from a phase III randomized trial.
Journal of Clinical Oncology, 2010:ASCO Annual Meeting Proceedings, Part I. Vol. 28, No 15S (Supplement)
R. von Moos, D. Patrick, L. Fallowfield, C. S. Cleeland, D. H. Henry, Y. Qian, R. D. Dansey, K. Chung.
Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with advanced cancer (excluding breast and prostate) or multiple myeloma (MM): Results from a randomized phase III clinical trial.
Journal of Clinical Oncology, 2010:ASCO Annual Meeting Proceedings, Part I. Vol. 28, No 15S (Supplement)
D. H. Henry, R. von Moos, V. Hungria, L. Costa, P. J. Woll, G. Scogliatti, J. Wang, S. Jun, R. D. Dansey, H. Yeh.
Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer.
Journal of Clinical Oncology, 2010: ASCO Annual Meeting Proceedings, Part I. Vol. 28, No 15S (Supplement)
R. Clemens B. Caspar, R. Steiner, R. Angst, R. Inauen, K. Schmieding, B. Thürlimann.
Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes.
Presented at the 2nd IBMS Davos Workshop: Bone Biology & Therapeutics, Davos, Switzerland, 14 – 19 March 2010
Cathomas R.
Therapieoptionen beim fortgeschrittenen Nierenzellkarzinom: update 2010.
Schweizerische Zeitschrift für Onkologie 4/2010, S.19 - 23.
Cathomas R.
Systemische Therapien beim Prostatakarzinom: eine Übersicht.
Facharzt Gynäkologie/Urologie (Österreich) 2010; 4: 14-18
Schmidt F, Cathomas R, Stallmach T, Putora PM, Müller J.
Have you ever heard of hibernoma? A rare but important pitfall in FDG PET/CT.
Nuklearmedizin 2010; 49: N71-73
Strebel R, Gillessen S, Huber U, Morant R, Sulser T, Cathomas R.
Behandlung und interdisziplinäre Zusammenarbeit beim Prostatakarzinom in der Schweiz: Resultate der Swissmove Erhebung.
Presented at SGU Jahrestagung 2010.
Cathomas R, Gillessen S, Huber U, Pless M, Morant R, Winterhalder R, Schmid HP, Sulser T, Strebel R.
Multidisciplinarity in the management of prostate cancer: results of a prospective observational study in Switzerland.
Ann Oncol 2010;21 (Suppl 8):302
Fehr M, von Moos R, Mayer G, Wieland T, Cathomas R.
The influence of cisplatin in porphyrin-metabolism: a pilot study based on a case observation.
Onkologie 2010; 33 (Suppl 6): 77-78
Fresard I, Weinberg U, Kueng M, Cathomas R, Buess M, Pless M, Kirson DE, Betticher DC. J Thorac.
An open label pilot study of tumor treating fields (TTFields) in combination with pemetrexed for advanced non small cell lung cancer.
Oncol 2010; 5: suppl. 15. Presented at European Lung Cancer Conference (Poster)
Cathomas R, Helbling D, Stenner F, Rothermundt C, Rentsch C, Shahin O, Seifert HH, Zaugg K, Lorch A, Mayer F, Beyer J, De Santis M, Gillessen S.
Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a joint effort.
Swiss Med Wkly 2010;140:356-369.
Jungi M, Cathomas R, Rothermundt C.
Radiation Recall Reaction.
Schweiz Med Forum 2010;13:255
Fehr M, Kuhn M, Mayer K, Padberg B, Ulmer U, Cathomas R.
Metastatic angiosarcoma arising from the right atrium: unusual presentation and excellent response to treatment in a young patient.
J Thorac Oncol 2010;5:1301-1302
Cathomas R, Köberle D, Ruhstaller T, Mayer G, Räss A, Mey U, von Moos R.
Heated (37° C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
Supp Cancer Care 2010;18:1263-1270
Fehr M, Kuhn M, Mayer K, Padberg B, Ulmer U, Cathomas R.
Metastatic angiosarcoma arising from the right atrium: oncological options in a rare disease.
Krebsbulletin Schweiz 2010;30:177-180
Mayer D, Cathomas R, Gadient G, Kuhn M.
Atemnot bei Astrozytom, wo ist der Zusammen-hang?
Schweiz Med Forum 2010;10:350-351
P. Keller, A. Angelillo-Scherrer, M. Bargetzi, J. Goede, U. Hess, P. Imbach, Th. Kühne, S. Mach-Pascual, U. Mey, A. Rüfer, A. Schmidt.
Diagnose und Behandlung der primären Immun-Thrombozytopenie.
Schweiz Med Forum 2010;10(50):875–883
Mey UJ.
Current treatment strategies for multiple myeloma.
Ther Umsch. 2010 Oct;67(10):527-35. Review. German
Simons S, Ringsdorf S, Braun M, Mey UJ, Schwindt PF, Ko YD, Schmidt-Wolf I, Kuhn W, Jaehde U.
Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.
Support Care Cancer. 2010 Jun 16
Taverna C, Bargetzi M, Betticher D, Gmür J, Gregor M, Heim D, Hess U, Ketterer N, Lerch E, Matthes T, Mey U, Pabst T, Renner C.
Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.
Swiss Med Wkly. 2010 Sep 13;140:w13054. Review
Taverna C, Desalmand D, Gmür J, Gregor M, Hess U., Ketterer N, Lerch E, Mey U, Pabst T, Passweg J, Renner Ch, Vögeli J.
Lenalidomid bei vorbehandeltem multiplem Myelom. Leitfaden für die Therapie.
Schweizer Zeitschrift für Onkologie 3/2010